Health
GSK Acquires Pulmonary Hypertension Biotech 35Pharma for $950 Million
Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.
Key Takeaways
- GSK to acquire 35Pharma for $950M in cash, closing expected Q2 2026
- 35Pharma's lead pulmonary hypertension candidate is in late-stage clinical trials
- Pulmonary hypertension affects 50-70 million people globally with limited treatment options
- Deal strengthens GSK's respiratory portfolio alongside its existing asthma and COPD franchises
DE
DT Editorial AI··via endpoints.news